Assays for hepatitis B surface antigen (HBsAg) are the most frequently used tests to detect HBV infection. Vaccination for HBV can produce transiently detectable levels of HBsAg in patients.
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).
Interim results from the phase 2b B-Clear showed that bepirovirsen reduced levels of hepatitis B surface antigen (HBsAg) and HBV DNA after 24 weeks' treatment to below the lower limit of detection ...
New model predicts HCC risk in noncirrhotic chronic hepatitis B patients, improving early detection strategies.
bepirovirsen at a dose of 300 mg per week over 24 weeks resulted in sustained hepatitis B surface antigen (HBsAg) and HBV DNA loss to below the limits of detection in 9% to 10% of participants ...
Irish Examiner on MSN20d
Research finds higher rates of HIV and Hepatitis B in Ireland than previously thoughtA study to determine the extent of such blood-borne infections in the community also found that the prevalence of Hepatitis B and HIV was 'significantly higher' in the Cork region ...
Discover a clinical trial that was conducted to evaluate the efficacy and safety of autologous HBV vaccine-pulsed dendritic cells and their induced T cells.
Thirty-four HBsAg tests were performed on 34 different patients within 14 days of a dose of Engerix-B® hepatitis B vaccine, with 24 of these occurrences involving patients with chronic renal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback